Home » Topics » BioWorld Science

BioWorld Science
RSS

Novartis studies CLL-442 in cutaneous squamous cell carcinoma in situ

April 5, 2018

Phase I trial studies BMS-986299 alone and with nivolumab and ipilimumab in advanced solid tumors

April 5, 2018

Abide Therapeutics discovers MGL and ABHD6 inhibitors

April 5, 2018

Pliant Therapeutics patents new integrin alphavbeta1 antagonists

April 5, 2018

A*STAR identifies novel MSP receptor-targeting antibodies

April 5, 2018

Kymera and GSK collaborate to accelerate discovery of protein-degrading therapeutics

April 5, 2018

Lilly and Sigilon collaborate on encapsulated cell therapies for type 1 diabetes

April 5, 2018

Novel gene fusion detected in BCR-ABL-negative leukemia

April 5, 2018

FDA allows IND for phase Ib/IIa study of AG-019 for early onset type 1 diabetes

April 5, 2018

FDA grants priority review to NDAs for omadacycline for CABP and ABSSSI

April 5, 2018

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 9, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 9, 2025.
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...
Brenig Therapeutics discovers new LRRK2 inhibitors
BioWorld Science
Brenig Therapeutics Inc. has described leucine-rich repeat kinase 2 (LRRK2; dardarin) and (LRRK2; dardarin) (G2019S mutant) inhibitors reported to be useful for...